Indiana University

Advanced Research & Technology Institute

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Michael J Kubek

Abraham Jacob Domb

Domb Abraham Jacob

Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.

Nanoparticle compositions

Methods and compositions are disclosed for providing prolonged-release of therapeutic agents by way of in situ stereotaxic implantation in specific loci, including pathways, to treat know disorders. One or more microstructures comprising therapeutic agents and pharmaceutically acceptable carriers are implanted, for example, through a cannula. The microstructures are of a sufficient size and shape to prevent dispersion from the implant site.

Method for modulating glutamate and/or aspartate release in a central nervous system locus

The present invention is directed to a method of modulating the release of at least one endogenous compound in vivo. The method comprises delivering intranasally at least one micro-construct comprising an agonist and a pharmaceutically acceptable carrier to a locus comprising an agonist receptor and a heterologous receptor that is coupled to at least one common signaling molecule. The micro-construct used in the present inventive method provides sustained release of the agonist provided by erosion of an exterior surface defined by the micro-construct. Once released, the agonist effectively up- or down-regulates at least one signaling molecule common to both the agonist receptor and the heterologous receptor, thereby potentiating or desensitizing the heterologous receptor in order to modulate release of at least one endogenous compound under the control of the heterologous receptor.

Pharmacotherapeutic process and composition for central nervous system disorders

Methods and compositions are disclosed for providing prolonged-release of therapeutic agents by way of in situ stereotaxic implantation in specific loci, including pathways, to treat known disorders. One or more microstructures comprising therapeutic agents and pharmaceutically acceptable carriers are implanted, for example, through a cannula. The microstructures are of a sufficient size and shape to prevent dispersion from the implant site.

Methods and compositions are disclosed for providing prolonged release of therapeutic agents by way of in situ stereotaxic implantation in specific loci, including pathways, to treat known disorders. One or more microstructures comprising therapeutic agents and pharmaceutically acceptable carriers are implanted, for example, through a cannula. The microstructures are of a sufficient size and shape to prevent dispersion from the implant site.

Growing community of inventors

Indianapolis, IN, United States of America

Michael J Kubek